Good morning. Elizabeth Cooney here, filling in for Ed Silverman this week as he makes those daydreams of vacation plans come true. Here’s what we’re watching today from Boston HQ:
Guardant Health has published results saying its blood test could replace biopsy for rare cancer treated by Keytruda, STAT reports. Currently, identifying such cancers, called MSI-High, for “microsatellite instable-high,” requires examining a tumor that had been surgically removed. Merck’s (MRK) Keytruda is approved to treat tumors that appear anywhere in the body, but are marked with a specific genetic signature.